The Guideline for the prophylactic use of RhD immunoglobulin in pregnancy care was released on 28 May 2021, and is available on the NBA website. The Guideline introduces new clinical guidance on the use of non-invasive prenatal testing (NIPT) to determine fetal RHD status.

This guidance is based on scientific evidence and consensus among clinical experts and is not a policy statement on funding and supply arrangements for the national provision of NIPT which are currently being considered by government.

Lifeblood has recently written to Approved Health Providers advising that our Red Cell Reference laboratory is currently only approved to provide NIPT for RHD in pregnant women at high risk of RhD haemolytic disease of the fetus and newborn (HDFN) (i.e. alloimmunised women with preformed anti-D).